Nature Biotechnology

doi: 10.1038/nbt0807-821pmid: 17687342

The example set by leading proteomics laboratories will be a major factor in determining the successful implementation of new reporting guidelines in the wider community.

doi: 10.1038/nbt0807-822pmid: 17687343

Despite hand-wringing over the patenting of a minimized organism, both patents and open-source approaches will be needed to promote innovation and research progress in synthetic biology.

Sheridan, Cormac

doi: 10.1038/nbt0807-823pmid: 17687344

Several large deals may signal reentry of big pharma into the space

Schmidt, Charlie

doi: 10.1038/nbt0807-825pmid: 17687345

Cancer failures are not deterring interest in toll-like receptor agonists for other high profile indications.

Fox, Jeffrey L

doi: 10.1038/nbt0807-827pmid: 17687346

Glimmers of hope around cancer vaccines are tempered by confusion over clinical trial endpoints

Shaffer, Catherine

doi: 10.1038/nbt0807-829pmid: 17687347

Local talent, wishing to stay in the area, is stimulating startup formation.

doi: 10.1038/nbt0807-831pmid: N/A

Lawrence, Stacy

doi: 10.1038/nbt0807-833pmid: 17687349

Jia, Hepeng

doi: 10.1038/nbt0807-835pmid: 17687350

When Zheng Xiaoyu took the helm of the Chinese State Food and Drug Administration (SFDA) nine years ago, hopes were high for effective regulatory oversight of China's drug industry. Now those hopes have been dashed with tragic personal consequences for Zheng and allegations of widespread corruption by Chinese officials.

Garber, Ken

doi: 10.1038/nbt0807-838pmid: 17687351

Despite the high-profile failures of two more stroke drugs in late-stage trials, biotech firms are persevering with new approaches and treatments.